F. Hoffmann-La Roche AG: Impact Healthcare Roche Sequencing is not only changing science, but we are changing lives. Our software teams are laying the groundwork for the fu... Mississauga, Ontario, Canada

Integrated Resources, Inc: Job title: Bioinformatics Scientist Job Location: Remote Job Duration: 12+ months Job Description: Contractor Role - Functional Genomics Integrativ... Atlanta, Georgia

Exact Sciences: Help us change lives At Exact Sciences, we're helping change how the world prevents, detects and guides treatment for cancer. We give patients and ... San Diego, California

Notice NOT-NS-24-054 from the NIH Guide for Grants and Contracts

Notice NOT-DA-25-029 from the NIH Guide for Grants and Contracts

Notice NOT-AR-24-006 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-002 from the NIH Guide for Grants and Contracts

Guardant Health: DEPARTMENT SUMMARY - The Bioinformatics, BioPharma team at Guardant Health is focused on partnerships with leading biotech and pharma companies wh... Palo Alto, California

Guardant Health: About the Role: We are seeking an inspired and motivated learner to join our team and actively participate in the exploration and development of i... San Diego, California

Notice NOT-NR-24-006 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-025 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-052 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-23-011 from the NIH Guide for Grants and Contracts. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) that were developed for the treatment of type 2 diabetes (T2D) have significant protective effects for cardiac and renal diseases for people with and without diabetes. However, SGLT2i are not currently approved for individuals with type 1 diabetes (T1D) and there is an increased risk of diabetic ketoacidosis (DKA) for this population. Despite this concern, these drugs are increasingly being prescribed off-label for people with T1D. Continuous ketone monitoring (CKM) is a rapidly evolving technology that could be utilized clinically to prevent DKA by an early warning of elevations in ketone levels.The purpose of this NOFO is to solicit applications for studies that will develop and test risk mitigation strategies that involve the clinical integration of CKM for the safe use of SGLT2i for people living with T1D so that they may benefit from the cardiac and renal protection and glucose-lowering effects of this drug class. The NOFO will support short-term, clinical trials to gain and disseminate knowledge on safety and glucose control with CKM and SGLT2i use.Possible topics include testing optimal insulin delivery in open and closed loop systems or multiple daily injections and developing clinical protocols to control or ameliorate elevated ketone levels in individuals with T1D who are receiving adjunct therapy with SGLT2i.

Notice NOT-DA-23-063 from the NIH Guide for Grants and Contracts

Commensurate with Experience: Charles River: For 75 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When... Newark, United States

Funding Opportunity RFA-DA-25-053 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD) Areas of interest include but are not limited to: 1) Development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology 2) Development of assays to assess the effects of compounds on multiple targets or functions

Funding Opportunity RFA-DA-25-054 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD) Areas of interest include but are not limited to: 1) Development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology 2) Development of assays to assess the effects of compounds on multiple targets or functions

From £41,935 with benefits, subject to skills and experience: The Francis Crick Institute: The Genetic Mechanisms of Disease lab studies how genetic variation affects the normal functioning of the immune system. London (Central), London (Greater)

Notice NOT-OD-24-057 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-099 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program provides support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High- risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and may be proposed under this program.